Moderna beats on revenue but loses more than expected as it scales down manufacturing
1. Moderna reported a Q4 net loss of $1.12 billion, exceeding expectations. 2. Revenue fell to $966 million, significantly below last year's $2.8 billion. 3. Covid vaccine sales declined 66%, prompting concerns over competition and demand. 4. Company aims to introduce 10 new mRNA products in three years. 5. Expectations for 2025 revenue guidance range from $1.5 billion to $2.5 billion.